Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis.

ABSTRACT:

Background/aims

A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by metaanalysis.

Methods

The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines.

Results

Three RCTs (n = 98) and tw

SUBMITTER: Lee HY 

PROVIDER: S-EPMC6406097 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature